Document Detail


Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
MedLine Citation:
PMID:  19652526     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Bone metastasis affects the majority of patients with advanced breast cancer and no adequate therapy exists. Bisphosphonates, like zoledronic acid, inhibit the osteolytic component of tumor growth in osseous tissues, but these drugs are not curative. The current study evaluated the combination of zoledronic acid with death receptor 5 agonists in an animal model of breast cancer bone metastasis. MATERIALS AND METHODS: Female athymic nude mice (age 4-6 weeks, n=35) were inoculated with 200,000 luciferase-positive MDA- MB-435 cells by injection into the left ventricle. Animals were immediately imaged by bioluminescence technique and placed into one of the following therapy groups: Saline, hTRA8, hTRA8 + zoledronic acid, mTRA8, mTRA8 + zoledronic acid, or zoledronic acid monotherapy. DR5 agonists were given at 200 microg/dose and zoledronic acid 5 microg/dose, with mice treated biweekly for 4.5 weeks and imaged weekly. RESULTS: Combination therapy containing either hTRA8 or mTRA8 with zoledronic acid significantly reduced the number of secondary lesions (7.67+2.2 and 7.5+1.7 lesions/mouse, respectively) compared to saline treated controls (12.1+/-1.56 lesions/mouse) as assessed by bioluminescence imaging (p<0.05). Additionally, monotherapy with hTRA8 resulted in a significant reduction in tumor number (8.3 +/- 2.9) compared to control animals. Total body tumor burden over time were significantly less in groups treated with hTRA8+zoledronic and mTRA8 + Zoledronic acid combination as compared with the saline control group. At day 33, both combination therapies and zoledronic acid monotherapy provided significant reduction in total tumor burden and tumor infiltration of hindlimbs by histomorphometry (p<0.05). CONCLUSION: DR5 agonists in combination with bisphosphonates may be an acceptable combination therapy to reduce breast cancer growth in bone.
Authors:
April Adams Szafran; Karri Folks; Jason Warram; Diptiman Chanda; Deli Wang; Kurt R Zinn
Related Documents :
785936 - Tranexamic acid (amca) and late hyphaema. a double blind study in cataract surgery.
21875796 - 2,5-disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design a...
21894886 - Efficient and scalable one-pot synthesis of 2,4-dienols from cycloalkenones: optimized ...
3917666 - Oxidation and glucuronidation of valproic acid in male rats--influence of phenobarbital...
11354146 - Triterpenoid saponins from the leaves of ilex kudincha.
17136306 - Fatty acids reduce the tensile strength of fungal hyphae during cephalosporin c product...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer biology & therapy     Volume:  8     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-08-06     Completed Date:  2009-12-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1109-16     Citation Subset:  IM    
Affiliation:
Department of Pathology, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35294-0019, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies, Monoclonal / administration & dosage,  pharmacology*
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
Apoptosis / drug effects
Bone Density / drug effects
Bone Density Conservation Agents / administration & dosage,  pharmacology
Bone Neoplasms / drug therapy,  prevention & control*,  secondary*
Breast Neoplasms / drug therapy*,  pathology
Cell Line, Tumor
Diphosphonates / administration & dosage,  pharmacology*
Female
Humans
Imidazoles / administration & dosage,  pharmacology*
Mice
Mice, Nude
Osteoclasts / drug effects,  pathology
Receptors, TNF-Related Apoptosis-Inducing Ligand / agonists*,  immunology
Xenograft Model Antitumor Assays
Grant Support
ID/Acronym/Agency:
5P30 CA 013148-36/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 118072-93-8/zoledronic acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Utility of the systemic inflammatory response syndrome (SIRS) criteria in predicting the onset of se...
Next Document:  Spermidinyl-CoA-based HAT inhibitors block DNA repair and provide cancer-specific chemo- and radiose...